| Strategic Energy Resources Limited (SER) ORDINARY FULLY PAID |
Materials |
$7 |
Update to Appendix 2A - 1 August 2025
|
8 Aug 2025 9:13AM |
$0.006 |
$0.006 |
fallen by
0%
|
|
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$30 |
Application for quotation of securities - BTN
|
8 Aug 2025 9:12AM |
$0.086 |
$0.080 |
fallen by
6.98%
|
|
| Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID |
Health Care |
$33 |
Bioshares Biotech Summit Presentation
|
8 Aug 2025 9:11AM |
$0.685 |
$0.260 |
fallen by
62.04%
|
|
| Platinum Capital Limited (PMC) ORDINARY FULLY PAID |
Financials |
$449 |
Weekly Net Tangible Asset Backing
|
8 Aug 2025 9:09AM |
$1.420 |
$1.765 |
risen by
24.30%
|
|
| Platinum Asia Investments Limited (PAI) ORDINARY FULLY PAID |
Financials |
- |
Weekly Net Tangible Asset Backing
|
8 Aug 2025 9:09AM |
$1.165 |
$0.970 |
fallen by
16.74%
|
|
| Washington H. Soul Pattinson and Co. Limited (SOL) ORDINARY FULLY PAID |
Financials |
$13,457 |
SOL Despatch of Notice of Meeting and Proxy Form
|
8 Aug 2025 9:07AM |
$42.160 |
$35.420 |
fallen by
15.99%
|
|
| Osteopore Limited (OSX) ORDINARY FULLY PAID |
Health Care |
$2 |
Change in substantial holding
|
8 Aug 2025 9:06AM |
$0.011 |
$0.007 |
fallen by
36.36%
|
|
| Great Divide Mining Ltd (GDM) ORDINARY FULLY PAID |
Materials |
$15 |
Change of Director's Interest Notice - Adam Arkinstall
|
8 Aug 2025 9:06AM |
$0.410 |
$0.330 |
fallen by
19.51%
|
|
| Great Divide Mining Ltd (GDM) ORDINARY FULLY PAID |
Materials |
$15 |
Change of Director's Interest Notice - Paul Ryan
|
8 Aug 2025 9:05AM |
$0.410 |
$0.330 |
fallen by
19.51%
|
|
| Asian Investment Corporation Limited (ANV) ORDINARY FULLY PAID |
- |
- |
Next Interest Payment Date
|
8 Aug 2025 9:04AM |
n/a |
n/a |
n/a
|
|
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$198 |
Release of Supplementary Explanatory Memorandum
|
8 Aug 2025 9:04AM |
$0.315 |
$0.190 |
fallen by
39.68%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- BETR Entertainment Limited (BBT) issued a supplementary explanatory memorandum on 16 May 2024.
- The memorandum supplements previous disclosures about the proposed acquisition of BBT by BETR.
- It provides further clarification in response to shareholder and regulatory queries.
- Financial and strategic rationales for the acquisition are detailed.
- Implications for shareholders, including benefits and risks, are discussed.
- Updates on the regulatory approval process are provided.
- The board maintains its recommendation that shareholders vote in favor of the acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$198 |
Supplementary Explanatory Memorandum (Selective Buy-Back)
|
8 Aug 2025 9:04AM |
$0.315 |
$0.190 |
fallen by
39.68%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- The Memorandum supplements the original Explanatory Memorandum dated 22 May 2023.
- BETR Entertainment Limited (formerly BBT Entertainment Limited) proposes a Selective Buy-Back of shares.
- The document explains the rationale for the buy-back and its anticipated advantages for the company and its shareholders.
- Details of the buy-back process, including legal, financial, and regulatory aspects, are provided.
- The Memorandum outlines procedural aspects and voting requirements for shareholders at the upcoming general meeting.
- Independent expert advice is summarized regarding the fairness and reasonableness of the buy-back proposal.
- Directors offer their recommendations and disclose updates or corrections to prior disclosures.
- The document discusses the impact of the buy-back on shareholder interests, company control, and potential tax implications.
- Shareholders are encouraged to review all materials and consider seeking independent advice before voting.
- The Supplementary Memorandum aims to ensure full transparency and inform shareholder decision-making ahead of the buy-back resolution.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brickworks Limited (BKW) ORDINARY FULLY PAID |
Materials |
- |
BKW - Despatch of Notice of Meeting and proxy form
|
8 Aug 2025 9:03AM |
$34.500 |
$33.020 |
fallen by
4.29%
|
|
| COSOL Limited (COS) ORDINARY FULLY PAID |
Information Technology |
$81 |
FY25 Full Year Results Investor Call Details
|
8 Aug 2025 9:03AM |
$0.585 |
$0.448 |
fallen by
23.50%
|
|
| Osteopore Limited (OSX) ORDINARY FULLY PAID |
Health Care |
$2 |
OSX & Universiti Malaya initiate dental bone healing trial
|
8 Aug 2025 9:00AM |
$0.011 |
$0.007 |
fallen by
36.36%
|
|
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$866 |
Approval to Escalate Dosing in Kidney Disease Clinical Trial
|
8 Aug 2025 8:59AM |
$1.245 |
$1.485 |
risen by
19.28%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC Therapeutics Limited has received approval from the Data Safety Monitoring Board (DSMB) to escalate dosing in its Phase 1 clinical trial for patients with autosomal dominant polycystic kidney disease (ADPKD).
- The DSMB approval follows the successful completion of the initial single ascending dose cohort in the trial, with no safety concerns observed.
- The first-in-human trial evaluates PYC’s lead investigational drug, PYC001, intended to treat ADPKD, a chronic kidney disorder with significant unmet medical need.
- The trial's primary objective is to assess the safety, tolerability, and pharmacokinetics of PYC001 in ADPKD patients.
- The dosing escalation marks an important milestone for the clinical development of PYC001 and supports PYC’s broader pipeline strategy.
- PYC Therapeutics will continue advancing its research and development efforts with a focus on genetically defined kidney diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| COSOL Limited (COS) ORDINARY FULLY PAID |
Information Technology |
$81 |
Update on FY25 Performance
|
8 Aug 2025 8:59AM |
$0.585 |
$0.448 |
fallen by
23.50%
|
|
COS - Price-sensitive ASX Announcement
Full Release
Key Points
- COSOL Limited updates the market on its FY25 performance outlook.
- The company is experiencing reduced project work from clients, particularly in APAC.
- Actions are being taken to manage costs and improve operational efficiency.
- COSOL is focusing on renewing client engagement and expanding digital solutions.
- Growth and diversification of revenue streams remain strategic priorities.
- The company remains committed to long-term growth despite current challenges.
- Active risk management is underway to mitigate near-term headwinds.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$101 |
Notification of cessation of securities - CAM
|
8 Aug 2025 8:58AM |
$0.710 |
$0.690 |
fallen by
2.82%
|
|
| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$136 |
Change in Substantial Holding
|
8 Aug 2025 8:56AM |
$0.440 |
$0.945 |
risen by
114.77%
|
|
| EML Payments Limited (EML) ORDINARY FULLY PAID |
Financials |
$312 |
Change of Business Addresses
|
8 Aug 2025 8:56AM |
$1.080 |
$0.805 |
fallen by
25.46%
|
|
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$101 |
Update - Notification of buy-back - CAM
|
8 Aug 2025 8:55AM |
$0.710 |
$0.690 |
fallen by
2.82%
|
|
| Piedmont Lithium Limited (PLL) ORDINARY FULLY PAID |
Materials |
- |
Piedmont Lithium Reports Q2 2025 Results
|
8 Aug 2025 8:55AM |
$0.130 |
$0.140 |
risen by
7.69%
|
|
PLL - Price-sensitive ASX Announcement
Full Release
Key Points
- PLL reported progress on Carolina Lithium and Tennessee Lithium projects during Q2 2025.
- The company strengthened supply and offtake agreements to secure its position in the lithium market.
- Capital expenditures and financial strategies were outlined to support ongoing project development.
- PLL emphasized sustainability, compliance, and community relations as core business priorities.
- Anticipated milestones for 2025 and 2026 were detailed, focusing on project advancement and shareholder value.
- Partnerships and investments were highlighted as key drivers of future growth.
- Operational updates included advancements in permitting, construction, and project timelines.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Loyal Metals Ltd (LLM) ORDINARY FULLY PAID |
Materials |
$42 |
Application for quotation of securities - LLM
|
8 Aug 2025 8:54AM |
$0.200 |
$0.280 |
risen by
40%
|
|
| MA Credit Income Trust (MA1) ORDINARY UNITS FULLY PAID |
- |
$572 |
Daily Estimate NTA for 06.08.2025
|
8 Aug 2025 8:53AM |
$2.070 |
$2.000 |
fallen by
3.38%
|
|
| Kali Metals Limited (KM1) ORDINARY FULLY PAID |
Materials |
$16 |
Change of Company Secretary
|
8 Aug 2025 8:51AM |
$0.160 |
$0.180 |
risen by
12.50%
|
|